Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014

| Source: Orion Orion 


ORION CORPORATION        STOCK EXCHANGE RELEASE 19 NOVEMBER 2013 at 12:10 p.m.
EET


The following change has been made in the responsibility areas of Orion Group
Executive Management Board as of 1 January 2014:

Mr. Markku Huhta-Koivisto, Senior Vice President responsible for Specialty
Products and Fermion business divisions and Dr. Liisa Hurme, Senior Vice
President responsible for Proprietary Products business division will exchange
their responsibility areas. Thus, as of 1 January 2014, Markku Huhta-Koivisto,
Senior Vice President, will be responsible for Proprietary Products business
division, and Liisa Hurme, Senior Vice President, will be responsible for
Specialty Products and Fermion business divisions.

They both continue to be members of the Orion Group Executive Management Board
as previously.

Timo Lappalainen, President and CEO, says:

"I am pleased that we can develop the Executive Management Board's operations in
a flexible way by this exchange of responsibility areas. I believe that the
change will give, not only a good possibility for Liisa and Markku for job
rotation, but also that it will bring positive effects for the whole Executive
Management Board and the company."



Orion Corporation



 Timo Lappalainen      Olli Huotari
 President and CEO     SVP, Corporate Functions



Contact person:
Timo Lappalainen, President and CEO, phone: +358 50 966 3692




Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1744144]